EMA Publishes Plan to Deal with Supply Shortages - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Publishes Plan to Deal with Supply Shortages


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency has published a plan to help Europe’s regulatory network prevent, mitigate, and manage shortages of important medicines following manufacturing problems.

Shortages of medicines arising from unforeseen disruptions within manufacturing processes, such as GMP compliance issues, have increased in recent years. However, experience from these shortages has enabled the EMA to identify several short- and medium-term actions that will help to deal with future occurrences. These actions are outlined in the EMA’s reflection paper on medicinal product supply shortages caused by manufacturing/Good Manufacturing Practice Compliance problems.

Some of the actions being taken in the short term include, among others:

  • Creating a public catalogue of current shortages
  • Establishing standard operating procedures for handling reports of shortages
  • Develop international cooperation to enable information sharing for specific shortages and on best practices on risk management and prevention strategies
  • Raise the awareness of the impact of medicine shortages and stimulate industry reaction and improvements.

In the medium term, the EMA hopes to:

  • Facilitate risk–benefit evaluation where risk shortage has to be balanced with potential risk because of the presence of a product defect.
  • Require all marketing authorization holders to submit a risk analysis of their manufacturing processes to identify weaknesses, and contingency plans to strengthen these points.
  • Investigate processes that could be used to measure the impact of medicines in patients.
  • Promote better and proactive risk management by marketing authorization holders.

According to EMA, several trends have converged to increase the number of medicines’ shortage. One of the major contributing factors is the globalization of supply chains and manufacturing networks.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here